Our mission is to enable cancer patients to benefit from the advantages of an autologous blood transfusion. We potentially can contribute to an optimized outcome of oncological surgeries reducing the side effects accompanied with allogeneic blood transfusion by developing the medical device CATUVAB® to remove cancer cells from intraoperative blood during cancer surgery to enable retransfusion of autologous blood.


Our goal is to enable retransfusion of tumor cell depleted autologous blood to patients during a cancer surgery and getting more independent from donor blood and its various side effects.

Furthermore, the replacement of donor blood is essential for groups which are not allowed to take blood from other people.

Meet our experienced Team

Lindis Blood Care was founded by Dr. Horst Lindhofer, developer of the first trifunctional antibody initially approved in Europe, Canada and Russia, and Dr. Franzpeter Bracht, former CEO/CBO of several Life Science companies.

Dr. Franzpeter Bracht
Dr. Franzpeter BrachtFounder / Managing Director: Strategy, Finance and Business Development
1/2018 Foundation of Lindis Blood Care GmbH including seed investment (Bracht Beteiligungsgesellschaft mbH)

2017 – 6/2018 COO of Celonic AG, Basel CH & Celonic Deutschland GmbH & CoKG, Heidelberg, Germany

2007 – 2017 CFO/COO of Glycotope GmbH and Affiliates

  • Developing of 3 antibodies to Phase IIb and one Glycoprotein up to Phase III
  • Responsible for finance, business development / marketing & sales and operations
  • Selling of Glycotope Biotechnology GmbH (CDMO) to Celonic AG, Basel

2007/2008 NexiGen GmbH

Foundation, financing and successful license / trade sale deal

2006 Foundation of Bracht Beteiligungsgesellschaft mbH (BBG)

2002 – 2006 CEO/CFO of Aplagen GmbH

  • Developing of anti PL Antibodies to clinical Phase I
  • Projects partnered with Lonza AG, Basel, CH and Bayer AG, Leverkusen, Germany

1997 – 2001 Kienbaum Management Consultants GmbH
Principal & Department Head Pharma & Life Sciences

1996 – 1997 Ernst & Young AG

Ph.D. (Dr. rer.nat.) at the Institute for Pharmacology and Toxicology at the University of Düsseldorf

Dr. Horst Lindhofer
Dr. Horst LindhoferFounder / Managing Director: Research & Development
1/2018 Foundation of Lindis Blood Care GmbH to develop a medical device

2017 Licensing agreement signed with an international partner for the development of several antibodies

2014-2016 Acquired selected assets developed by TRION Pharma

2010 “Galenus von Pergamon” Award for Removab in the category “Specialist Care”

2010 Founder of Lindis Biotech GmbH

2009 Step Award for Trion Pharma for “Product/Technology”

2009 Approval of Removab (Catumaxomab) in Europe

2002 AIO Award of the German Cancer Association, Berlin, for great contribution to tumor-biological research and development

12.1998 Co-Founder and CEO of TRION Research GmbH

05.1998 Signing of a cooperation, distribution and licensing agreement with Fresenius

03.1998 Co-Founder and CEO of TRION Pharma GmbH

1994 Recipient of the New Investigator Award at the 23rd ISEH Congress (International Society of Experimental Hematology), Minneapolis, USA for the development of a new manufacturing process of bispecific antibodies and first results in in vivo therapy

1992-1997 Research scientist at the GSF Institute for Immunology, together with the Munich University Hospital. During his tenure, Dr. Lindhofer was head of the clinical cooperation group “Bispecific Antibodies and Tumor Immunotherapy”. He started his academic work with the improvement of existing bispecific antibody approaches and laid the foundation for the development of the triomab® concept towards an innovative and modular platform technology

Dr. Lindhofer is the author of more than 50 publications, developer of numerous patents in the field of immunotherapy and has received several international awards

Ph.D. in Virology, Max-von-Pettenkofer Institute, Ludwig-Maximilians-Universität (LMU), Munich

Our Scientific Advisory Board

Neil Blumberg
Neil Blumberg
Neil Blumberg, MD, is Professor of the Department of Pathology and Laboratory Medicine at the University of Rochester Medical Center and Director of the Transfusion Medicine Unit, Blood Bank, and Stem Cell Storage Facility. As an expert in the field of blood transfusion immunology, Dr. Blumberg has worked to enhance the quality, safety and efficiency of transfusion services at Strong Memorial Hospital and across the broader medical community. His long-standing clinical and research foci are immune cytopenias, supportive care for patients with hematologic malignancies and the immunologic sequela of transfusion therapy.
Dr. Ulrich Granzer
Dr. Ulrich Granzer
Dr. Ulrich Granzer, PhD, CEO Granzer Regulatory Consultants, Munich, Germany, has been operating a leading consultancy for regulatory affairs and clinical development in Munich since 2002. His background in pharmacy together with his industry experience provide him with an excellent overview of current drug development programs as well as detailed insights into the requirements of key regulatory authorities. He has held global responsibility for regulatory affairs at Bayer AG and BASF Pharma Knoll. He is a founding member & president of the board of the German Association of Regulatory Affairs, DGRA, as well as co-founder of the European Union Regulatory Affairs Group, EURAG, and a member of the Drug Information Association, DIA.
Professor Hartmut Link
Professor Hartmut Link
Professor Hartmut Link, MD, PhD, Professor of Medicine, is Managing Director of Onkodin GmbH, which develops and publishes digitized oncology treatment regimes, he works also in his Private Practice for Internal Medicine, Hematology & Oncology Kaiserslautern he is Member of the Guideline Commission of the German Cancer Society. He has been, for almost two decades, the head physician of the Clinic for Internal Medicine I at the Westpfalz Clinic Kaiserslautern where he specialized in hematology, oncology, stem cell transplantation and diabetology. He has conducted numerous national and international phase II-IV clinical trials.
Professor Aryeh Shander
Professor Aryeh Shander
Professor Aryeh Shander, MD, FCCM, FCCP, FASA, is Clinical Professor of Anesthesiology, Medicine and Surgery at Icahn School of Medicine at Mount Sinai; Chief of Department of Anesthesiology, Critical Care Medicine, Hyperbaric Medicine and Pain Management at Englewood Hospital and Medical Center; Director of Education for TeamHealth Anesthesia. In addition, he serves as President for the Society for the Advancement of Blood Management (SABM) and is a Fellow of the American College of Critical Care Medicine and the American College of Chest Physicians. Aryeh Shander has also founded and is a member of several committees, in leading positions, such as: National Anemia Action Council (NAAC), the American Society of Critical Care Anesthesiologists (ASCCA), the American Association of Blood Banks (AABB), and the American Society of Anesthesiologists (ASA) where he serves as Chair of Committee on Patient Blood Management.
Bruce D Spiess
Bruce D Spiess
Bruce D Spiess, MD, FAHA, is Emeritus Professor of Anesthesiology and Associate Chair for Research at the University of Florida. He was the Vice Chairman of Anesthesiology at Virginia Commonwealth University in Richmond, for over 17 years and, later on, the Chief of Cardiothoracic Anesthesiology at the University of Washington.
Professor Kai Zacharowski
Professor Kai Zacharowski
Professor Kai Zacharowski, MD, PhD, ML FRCA, FESAIC; Director of the Department of Anesthesiology, Intensive Care Medicine and Pain Therapy at the University Hospital Frankfurt; Kai Zacharowski is an anesthesiologist, intensive care physician and clinical pharmacologist and former President of the European Society of Anesthesiology and Intensive Care. Focal points of his research are risks in anesthesiology and intensive care medicine, the complex interaction of the immune and coagulation systems, blood poisoning (sepsis) and patient blood management.

blood management
for cancer surgery

CATUVAB® – a new MEDICAL DEVICE to remove cancer cells reliably from intraoperative blood during IBS

Contact Us